Highlights
1 patent
About
Orally Administered Drug for Type-1 Diabetes
DUN T1 is an early-stage R&D company that develops an orally administered drug for type 1 diabetes. DUN T1's vision is to develop a proactive approach towards treatment and early diagnosis. DUN T1's novel natural ingredient is patented, safe, and effective.
Identity
| Name | DUN T1 |
|---|---|
| Slug | dun-t1 |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4I-LoosJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Meishar |
| HQ address | HaDuhifat Street 34, Meishar, Israel |
Web & social
| Website | https://www.dunica.info/ |
|---|---|
| https://www.linkedin.com/company/18844730 | |
| YouTube | https://www.youtube.com/channel/UC2AMbPElxCcDQv5H2qLVVMA |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Commerce & RetailDistribution ChannelsDistributorHealthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business models
B2B2C
Tags
patientschildrenpharma-companiespharmaceuticalsdrug-discoverychronic-patientschronic-diseasetreatmentsnatural-active-ingredientsdiabetesoral-drugs
Funding
| Total raised | $45K |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}